Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

06. Juni 2019 09:30 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Signs Agreement for Advanced Oral Tablet Technology in Treating Inflammatory Bowel Disease

BEVERLY, Mass., June 06, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, has signed an agreement with BDD Pharma, an...
29. Mai 2019 09:30 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals to Attend 2019 BIO International Convention, June 3-6

BEVERLY, Mass., May 29, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that the Company will be...
21. Mai 2019 09:30 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals At Digestive Disease Week Conference, Nears Selecting Drug Formulation Company to Prepare Oral Brilacidin for Targeted Delivery in Ulcerative Colitis

BEVERLY, Mass., May 21, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that the...
16. Mai 2019 09:30 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Announces Non-Binding Term Sheet Signed with Global Pharmaceutical Company to Develop and Commercialize Brilacidin for the Treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis

BEVERLY, Mass., May 16, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has signed...
01. Mai 2019 09:30 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Receives FDA End-of-Phase 2 Meeting Minutes

BEVERLY, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today it has received Food and Drug...
23. April 2019 09:30 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals - "JAMA" Article Reinforces Need for Novel Oral Mucositis Treatments in Supportive Cancer Care; Company progresses through first stage of review by European Medicines Agency (EMA) regarding Scientific Advice for planned Phase 3 Program

BEVERLY, Mass., April 23, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders of a recent...
16. April 2019 09:30 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Reports p53 Drug Candidate Therapeutic Potential Further Supported by Academic Research in Leukemias and in Combination with Cancer Immunotherapies

BEVERLY, Mass., April 16, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report recent academic and...
09. April 2019 08:30 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Reports Enhancements in Manufacture of Brilacidin Phase 3 Drug Supply

BEVERLY, Mass., April 09, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has...
28. März 2019 08:30 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals European Subsidiary, IPIX Pharma Ltd., Granted Meeting with European Medicines Agency (EMA) to Discuss International Phase 3 Brilacidin Oral Mucositis Program

BEVERLY, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today that the European Medicines...
15. März 2019 08:00 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Requesting European Medicines Agency (EMA) Input for International Phase 3 Brilacidin Oral Mucositis Program

BEVERLY, Mass., March 15, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that...

Vorherige Seite

Nächste Seite